GlassScriptPhysician profile
Farzad Majidi
NPI 1699735282
$6,915.08
in general payments reported to CMS, 2019-2025
27 companies · $618 in 2025
The $618 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $266 · 2021: $1,260 · 2022: $1,410 · 2023: $1,381 · 2024: $647 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,268.37 | 2020-2023 | Impella |
| Amgen INC. | $900.39 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $753.33 | 2021-2024 | Diamondback Coronary, Coroflow |
| E.R. Squibb & Sons, L.L.C. | $445.86 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $423.83 | 2019-2025 | |
| Boston Scientific Corporation | $382.54 | 2019-2023 | |
| Medtronic Vascular, INC. | $323.88 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $320.77 | 2021-2025 | Verquvo, Winrevair |
| Medtronic, INC. | $298.57 | 2021-2024 | Ffrangio |
| Cardiovascular Systems INC. | $264.20 | 2019-2023 | Diamondback Coronary |
| Biotronik INC. | $251.40 | 2019 | |
| Penumbra, INC. | $200.10 | 2023 | Indigo System |
| Alnylam Pharmaceuticals INC. | $167.53 | 2025 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $160.35 | 2021-2025 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.79 | 2019-2024 | Lifevest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $109.57 | 2023-2025 | |
| Companion Medical, INC. | $90.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.07 | 2023-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $85.67 | 2023-2024 | Inpefa |
| Heartflow, INC. | $59.43 | 2022 | |
| Janssen Pharmaceuticals, INC | $47.61 | 2019-2021 | |
| Shockwave Medical, INC | $37.37 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $31.38 | 2024 | Arcalyst |
| Allergan, INC. | $26.60 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $24.93 | 2023 | Farxiga |
| Cvrx, INC. | $20.22 | 2023 | Barostim Neo System |
| Daiichi Sankyo INC. | $19.32 | 2025 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farzad Majidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.